Documentos de O’Donnell M. | REDI

Regresar

Mostrando 3 resultados de: 3

Filtros aplicados

Palabras Claves: "rivaroxaban"

Subtipo de publicación

Publisher

European Heart Journal - Cardiovascular Pharmacotherapy(1)

Área temáticas

Enfermedades(3)

Cirugía y especialidades médicas afines(1)

Farmacología y terapéutica(1)

Medicina y salud(1)

Área de conocimiento

Medicina interna(2)

Enfermedad cardiovascular(1)

Objetivos de Desarrollo Sostenible

ODS 10: Reducción de las desigualdades(3)

ODS 3: Salud y bienestar(3)

ODS 17: Alianzas para lograr los objetivos(2)

ODS 9: Industria, innovación e infraestructura(1)

Año de Publicación

Origen

Palabras Claves

Coronary artery disease(1)

Peripheral artery disease(1)

Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis

Abstract: BACKGROUND: Patients treated with antithrombotic drugs are at risk of bleeding. Bleeding may be the

Palabras claves:

aspirin, hemorrhage, neoplasms, rivaroxaban

Aboyans V., Alings M., Anand S.S., Avezum A.J., Berkowitz S.D., Bhatt D.L., Bosch J.J., Connolly S.J., Cook-Bruns N., Eikelboom J.W., Felix Camilo, Fox K.A.A., Hart R.G., Maggioni A.P., Moayyedi P., O’Donnell M., Rydén L.E., Shestakovska O., Verhamme P.B., Widimsky P., Yusuf S., Zhu J.

Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy

Abstract: Background and Purpose: Covert brain infarcts are associated with cognitive decline. It is not known

Palabras claves:

aspirin, COGNITION, infarction, rivaroxaban, white matter

Avezum A.J., Berkowitz S.D., Bhatt D.L., Bosch J.J., Branch K.R.H., Casanova A., Connolly S.J., Dagenais G.R., DIaz R., Dyal L., Eikelboom J.W., Ertl G., Fox K.A.A., Hart R.G., Keltai K., Keltai M., Kim J.H., Liang Y., Liu L., Lonn E.M., Maggioni A.P., O’Donnell M., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Reeh K.W., Rydén L.E., Sharma M., Smith E.E., Störk S., Tonkin A.M., Varigos J.D., Vinereanu D., Yusuf S., Zhu J.

Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial

Abstract: Aims: To describe outcomes of patients with chronic coronary artery disease (CAD) and/or peripheral

Palabras claves:

aspirin, Coronary artery disease, Peripheral artery disease, rivaroxaban

Aboyans V., Alings M., Anand S.S., Avezum A.J., Bangdiwala S.I., Bhatt D.L., Bosch J.J., Branch K.R.H., Camillo Felix, Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.L., DIaz R., Eikelboom J.W., Ertl G., Fox K.A.A., Guzik T.J., Hori M., Ibrahim K.S., Kakkar A.K., Keltai K., Keltai M., Kim J.H., Lamy A., Lanas F., Leong D.P., Lewis B.S., Liang Y., Lonn E.M., Lopez-Jaramillo P., Maggioni A.P., Metsarinne K.P., Muehlhofer E., Neumann C., O’Donnell M., Parkhomenko A.N., Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Sharma M., Steg P.G., Stoerk S., Tasto C., Tonkin A.M., Torp-Pedersen C., Tyrwitt J., Vanassche T., Varigos J.D., Verhamme P.B., Vinereanu D., Widimsky P., Yusuf S., Zhu J.